A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in clinical investigation. Considering different target specificities...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Uwe Rix, Jacques Colinge, Katharina Blatt, Manuela Gridling, Lily L Remsing Rix, Katja Parapatics, Sabine Cerny-Reiterer, Thomas R Burkard, Ulrich Jäger, Junia V Melo, Keiryn L Bennett, Peter Valent, Giulio Superti-Furga
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2013-01-01
coleção:	PLoS ONE
Acesso em linha:	http://europepmc.org/articles/PMC3795025?pdf=render
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!